What are the topical corticosteroids and their potency classifications?

Topical Corticosteroid Potency Classification

Topical corticosteroids are classified into 7 classes (US system) or 4 classes (UK/international systems), ranging from Class I/superpotent (strongest) to Class VII/mild (weakest), with specific agents recommended based on anatomical location and disease severity.

Classification Systems

The evidence reveals significant variation between classification systems 1, with only weak-to-moderate agreement (κw 0.53-0.60) but strong correlation (r 0.71-0.77) between US, UK, and WHO systems. This creates confusion in clinical practice, as only 17% of patients understand how many potency levels exist 2.

US 7-Class System (Most Commonly Used)

Class I - Superpotent/Very High Potency

• Clobetasol propionate 0.05% (cream, ointment, foam, solution)
• Halobetasol propionate 0.05% (cream, ointment)
• Betamethasone dipropionate 0.05% (cream, ointment - augmented formulation)
• Flurandrenolide 0.1% (tape with occlusion)

3, 4

Clinical use: Body surfaces for 2-4 weeks maximum; efficacy rates 58-92% 5. Maximum weekly use should be ≤50g for clobetasol/halobetasol 5.

Class II - Potent/High Potency

• Desoximetasone 0.25% cream
• Halcinonide 0.1% solution
• Betamethasone dipropionate 0.05% (non-augmented)

5

Clinical use: Efficacy rates 68-74% 5.

Class III - Upper Mid-Strength

• Fluticasone propionate 0.005% ointment
• Triamcinolone acetonide 0.5% cream

5

Clinical use: Efficacy rates 68-69% 5.

Class IV - Mid-Strength

• Betamethasone valerate 0.1% foam
• Triamcinolone acetonide 0.1% cream
• Mometasone furoate 0.1% cream

5, 6

Clinical use: Efficacy rates 70-72% 5.

Class V - Lower Mid-Strength

• Hydrocortisone butyrate 0.1% cream
• Aclometasone dipropionate 0.05%
• Fluticasone propionate 0.05% cream

3, 5, 3

Clinical use: Efficacy rates 41% 5. Preferred for facial use 3.

Class VI - Mild

• Desonide 0.05%
• Fluocinolone acetonide 0.01% oil

3, 5, 3

Clinical use: Efficacy rates up to 83% for scalp formulations 5. Preferred for facial use 3.

Class VII - Least Potent

• Hydrocortisone 1-2.5% cream

3

Clinical use: Preferred for facial use 3. Limited efficacy for standard plaque psoriasis 7.

Anatomical Site-Specific Recommendations

Body/Trunk

Use Class I agents (clobetasol propionate, halobetasol propionate, betamethasone dipropionate) 3, 4

Face/Intertriginous Areas

Use Class V-VII agents (aclometasone, desonide, hydrocortisone 2.5%) 3, 4

Critical caveat: Lower potency agents should be used on face, neck, genitals, and body folds due to increased risk of atrophy 8, 4. The forearms are also susceptible to steroid atrophy and require caution 4.

Duration and Safety Parameters

• Class I steroids: 2-4 weeks maximum continuous use 5, 4
• Less potent agents: Can be used for longer courses under supervision 5, 8, 4
• Maintenance therapy: Twice weekly application of medium potency agents reduces flares 8
• Maximum weekly dose: ≤50g for clobetasol/halobetasol 5

Vehicle Effects on Potency

Important: Vehicle significantly alters potency. For example, flurandrenolide 0.1% functions as Class V when used as cream but Class I when used as tape due to occlusive effects 7. Ointments generally provide greater potency than creams for the same concentration 4.

Common Pitfalls

1. Patient confusion is widespread: 55.5% of patients correctly identify their steroid potency, with 8% of very potent users believing they use mild steroids 2
2. No universal labeling: Potency is not printed on tubes or packaging 2
3. Tachyphylaxis concerns are overstated: Studies show no true receptor down-regulation; perceived tachyphylaxis is primarily due to poor adherence 7, 5
4. Abrupt discontinuation risks rebound: Gradual tapering recommended, though optimal protocols remain undefined 5, 4